Lung Cancer / Mesothelioma
There’s a single lung cancer trial being presented 6/1/08 at ASCO’s Plenary Session, at which the most important cancer studies of the year are presented. This is on the FLEX trial that I described in a prior post, and which was already reported to be positive, at a press release all the way back in […]
0 CommentsI’ve spent a lot of the last few days, and in fact a fair bit of the last few weeks, working on a faculty presentation I’m doing at the ASCO meeting tomorrow evening. It’s providing commentary in what is called a poster discussion session, at which 25 posters are displayed for several hours, and […]
0 Comments Let’s round out the discussion of additional abstracts that will be worthy of further discussion based on their implications for clinical practice. Here are another five to add to the five I introduced in the last post.
6) Molecular signatures to predict which patients benefit from adjuvant chemo (abstract here): Using tissue from 133 patients […]
Now that ASCO has changed its policy and has published the vast majority of its abstracts online in the weeks preceding the annual meeting (next week, where most of the biggest developments in clinical cancer research are presented), we can peek at some of these summaries and determine many of the reports that are […]
2 CommentsWhen I first started OncTalk, there was a lot of buzz about celebrex (celecoxib) as a cancer drug, but almost all of it was among patients talking about it on the internet: oncologists watching the field hadn’t been impressed by the early returns, including this one (despite the fact that some of my earliest work […]
2 CommentsAs I’ve described in a prior post, there is some evidence that patients who develop a rash on tarceva (erlotinib) have an improved survival compared to patients who experience no skin toxicity on tarceva. The key question is whether this is an issue of under-dosing some patients, or if it’s just a correlate of overall immune […]
5 CommentsLast year, a provocative trial was presented at ASCO that compared early vs. later taxotere as second line therapy. I described that study here, and it showed a very significant improvement in progression-free survival (PFS) and a near significant improvement in overall survival (OS) for the recipients of taxotere immediately after four cycles of first line […]
7 CommentsIn past years, a huge book of abstracts, the approximately 250 word summaries for each study, were mailed out to members of ASCO (the American Society of Clinical Oncology) in mid-May, but they weren’t publicly available to anyone else until the time of the huge annual conference about 2-3 weeks later (where most of the biggest […]
0 CommentsAt the 1st ESMO-IASLC Lung Cancer Conference in Geneva last week I saw a presentation that I thought would interest this general readership. The study, presented by Dr Grossi, from Italy, is a retrospective review of 61 patients with advanced NSCLC of all subtypes treated with either Tarceva (erlotinib) or Iressa (gefitinib) […]
3 CommentsSo I’ve been invited to be on the faculty of a lung cancer conference in Kauai next month (yes, a good gig, but this is the first year that the flights are so expensive that I can’t bring my family to this normally very family-friendly event), and my topic is to argue in a […]
0 Comments
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
